Given the lack of traditionally druggable molecules in Hippo/YAP pathway, our data suggest an alternative way of targeting YAP, i.e., targeting ZDHHC15, at least in YAP‐ driven breast and ovarian cancers. Here, ZDHHC15 is linked to ovarian carcinoma.